Correlation study of expressions of silence signal regulating factor-1 and E-cadherin in gastric cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LI Minghui ¹ , DONG Yongjie ¹ , ZHAO Jingya ² , LI Yumei ¹ , FENG Yunzhang ¹ , HUO Shuang ³

1. The Second Department of General Surgery, Handan Central Hospital, Handan, Hebei 056001, P. R. China;
2. Department of Pathology, Handan Central Hospital, Handan, Hebei 056001, P. R. China;
3. Department of Scientific Research, Handan Central Hospital, Handan, Hebei 056001, P. R. China;

Corresponding author：

LI Minghui, Email: viki81@163.com

Keywords：

gastric cancer; silence signal regulating factor-1; E-cadherin; immunohistochemistry

DOI：

10.7507/1007-9424.201705035

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate expressions of silence signal regulating factor-1 (SIRT-1) and epithelial cadherin (E-cadherin) in gastric cancer and their clinical significances. Methods The immunohistochemistry SP technique was used to detect the expressions of SIRT-1 and E-cadherin in the gastric cancer tissues and their corresponding paracancerous gastric tissues. The relationship between the SIRT-1 expression and E-cadherin expression was analyzed using Spearman. Results The positive rate of the SIRT-1 protein expression in the gastric cancer tissues was significantly higher than that of the corresponding paracancerous gastric tissues (χ²=5.791, P=0.016). The SIRT-1 protein positive expression was related to the Lauren histological type of gastric cancer (χ²=4.941, P=0.026), in other words, in the intestinal type was significantly higher than that of the diffuse type, but which was not related to the age, gender, tumor size, tumor site, differentiation degree, TNM stage, or lymph node metastasis (P>0.05). While the positive rate of the E-cadherin protein expression in the gastric cancer tissues was significantly lower than that of the corresponding paracancerous gastric tissues (χ²=10.868, P=0.001), which in the intestinal type of gastric cancer was significantly lower than that in the diffuse type of gastric cancer (χ²=5.203, P=0.023), also not related to the age, gender, tumor size, tumor site, differentiation degree, TNM stage, or lymph node metastasis (P>0.05). There was a negative correlation between the SIRT-1 protein and the E-cadherin protein (r_s=–0.381, P=0.013). Conclusions Gastric cancer with higher SIRT-1 expression might be way to achieve tumor development through E-cadherin as a facilitator. Upregulation of SIRT-1 and declining of E-cadherin might play a possible role in intestinal type gastric cancer.

Citation： LI Minghui, DONG Yongjie, ZHAO Jingya, LI Yumei, FENG Yunzhang, HUO Shuang. Correlation study of expressions of silence signal regulating factor-1 and E-cadherin in gastric cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(1): 42-47. doi: 10.7507/1007-9424.201705035 Copy

1.	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-E386.
2.	Marqués-Lespier JM, González-Pons M, Cruz-Correa M. Current perspectives on gastric cancer. Gastroenterol Clin North Am, 2016, 45(3): 413-428.
3.	Soroush A. Surgical outcome in patients with gastrointestinal malignancies; a report from a large referral hospital, 2008-2010. Middle East J Dig Dis, 2013, 5(4): 201-208.
4.	Abdelmohsen K, Pullmann R Jr, Lal A, et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell, 2007, 25(4): 543-557.
5.	钱金锋, 杨其昌, 谢慧君, 等. 乳腺浸润性导管癌中上皮间质转化相关蛋白表达与临床病理特征和预后的关系. 中国普外基础与临床杂志, 2015, 22(5): 591-596.
6.	Jang M, Koh I, Lee SJ, et al. Droplet-based microtumor model to assess cell-ECM interactions and drug resistance of gastric cancer cells. Sci Rep, 2017, 7: 41541.
7.	Park EY, Woo Y, Kim SJ, et al. Anticancer effects of a new SIRT inhibitor, MHY2256, against HUMAN BREAST CANCEr MCF-7 cells via regulation of MDM2-p53 binding. Int J Biol Sci, 2016, 12(12): 1555-1567.
8.	Edatt L, Haritha K, Sruthi TV, et al. 2-Deoxy glucose regulate MMP-9 in a SIRT-1 dependent and NFkB independent mechanism. Mol Cell Biochem, 2016, 423(1-2): 197-206.
9.	Lin MH, Lee YH, Cheng HL, et al. Capsaicin inhibits multiple bladder cancer cell phenotypes by inhibiting tumor-associated NADH oxidase (tNOX) and sirtuin1 (SIRT1). Molecules, 2016, 21(7). pii: E849.
10.	Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.
11.	Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. Hoboken: John Wiley & Sons, 2009.
12.	Jang KY, Hwang SH, Kwon KS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol, 2008, 32(10): 1523-1531.
13.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
14.	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
15.	Ling S1, Li J, Shan Q, et al. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol, 2017, 11(6): 682-695.
16.	Ray U, Roy SS, Chowdhury SR. Lysophosphatidic acid promotes epithelial to mesenchymal transition in ovarian cancer cells by repressing SIRT1. Cell Physiol Biochem, 2017, 41(2): 795-805.
17.	Ghosh A, Sengupta A, Seerapu GPK, et al. A novel SIRT1 inhibitor, 4bb induces apoptosis in HCT116 human colon carcinoma cells partially by activating p53. Biochem Biophys Res Commun, 2017, 488(3): 562-569.
18.	Ye Z, Fang B, Pan J, et al. miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1. Oncol Rep, 2017, 37(6): 3244-3252.
19.	Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol, 2009, 185(2): 203-211.
20.	安晓静, 金昌洙, 曹璋, 等. SIRT1、β-catenin 在胃癌组织中的表达及临床意义. 滨州医学院学报, 2013, 36(2) : 94-96.
21.	赵伟, 陈锐, 刘芮菡, 等. 沉默信息调节因子 1 对胃癌侵袭的影响及其机理研究. 中国普外基础与临床杂志, 2014, 21(4): 425-431.
22.	Jiang B, Chen JH, Yuan WZ, et al. Prognostic and clinical value of Sirt1 expression in gastric cancer: A systematic meta-analysis. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(2): 278-284.
23.	He C, Zhou Z, Jiang H, et al. Epithelial-mesenchymal transition is superior to vessels-encapsulate tumor cluster in promoting metastasis of hepatocellular carcinoma: a Morphological Evidence. J Cancer, 2017, 8(1): 39-47.
24.	Zhang Y, An J, Lv W, et al. miRNA-129-5p suppresses cell proliferation and invasion in lung cancer by targeting microspherule protein 1, E-cadherin and vimentin. Oncol Lett, 2016, 12(6): 5163-5169.
25.	Zhao L, Li Z, Chen W, et al. H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition. Oncol Lett, 2017, 13(1): 363-369.
26.	Gao H, Lan X, Li S, et al. Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer. Tumour Biol, 2017, 39(5): 1010428317698368.
27.	Zhang J, Chen XY, Huang KJ, et al. Expression of FoxM1 and the EMT-associated protein E-cadherin in gastric cancer and its clinical significance. Oncol Lett, 2016, 12(4): 2445-2450.
28.	苏林, 辛彦. E-cadherin和FSP-1/S100A4 在胃癌及其癌前病变中的表达与临床病理意义. 现代肿瘤医学, 2014, 22(12): 2903-2908.
29.	刘铭, 李宏, 张开立, 等. 胃癌组织中 caveolin-1 和 E-cadherin 表达及相关性的研究. 中国癌症杂志, 2010,20(11): 806-110.
30.	Rong L, Wu J, Wang W, et al. Sirt 1 activator attenuates the bleomycin-induced lung fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT). Eur Rev Med Pharmacol Sci, 2016, 20(10): 2144-2150.
31.	Lu J, Zhang M, Huang Z, et al. SIRT1 in B[a]P-induced lung tumorigenesis. Oncotarget, 2015, 6(29): 27113-27129.
32.	Tian Z, Jiang H, Liu Y, et al. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1. Exp Cell Res, 2016, 343(2): 135-147.

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-E386.
2. Marqués-Lespier JM, González-Pons M, Cruz-Correa M. Current perspectives on gastric cancer. Gastroenterol Clin North Am, 2016, 45(3): 413-428.
3. Soroush A. Surgical outcome in patients with gastrointestinal malignancies; a report from a large referral hospital, 2008-2010. Middle East J Dig Dis, 2013, 5(4): 201-208.
4. Abdelmohsen K, Pullmann R Jr, Lal A, et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell, 2007, 25(4): 543-557.
5. 钱金锋, 杨其昌, 谢慧君, 等. 乳腺浸润性导管癌中上皮间质转化相关蛋白表达与临床病理特征和预后的关系. 中国普外基础与临床杂志, 2015, 22(5): 591-596.
6. Jang M, Koh I, Lee SJ, et al. Droplet-based microtumor model to assess cell-ECM interactions and drug resistance of gastric cancer cells. Sci Rep, 2017, 7: 41541.
7. Park EY, Woo Y, Kim SJ, et al. Anticancer effects of a new SIRT inhibitor, MHY2256, against HUMAN BREAST CANCEr MCF-7 cells via regulation of MDM2-p53 binding. Int J Biol Sci, 2016, 12(12): 1555-1567.
8. Edatt L, Haritha K, Sruthi TV, et al. 2-Deoxy glucose regulate MMP-9 in a SIRT-1 dependent and NFkB independent mechanism. Mol Cell Biochem, 2016, 423(1-2): 197-206.
9. Lin MH, Lee YH, Cheng HL, et al. Capsaicin inhibits multiple bladder cancer cell phenotypes by inhibiting tumor-associated NADH oxidase (tNOX) and sirtuin1 (SIRT1). Molecules, 2016, 21(7). pii: E849.
10. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.
11. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. Hoboken: John Wiley & Sons, 2009.
12. Jang KY, Hwang SH, Kwon KS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol, 2008, 32(10): 1523-1531.
13. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
14. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
15. Ling S1, Li J, Shan Q, et al. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol, 2017, 11(6): 682-695.
16. Ray U, Roy SS, Chowdhury SR. Lysophosphatidic acid promotes epithelial to mesenchymal transition in ovarian cancer cells by repressing SIRT1. Cell Physiol Biochem, 2017, 41(2): 795-805.
17. Ghosh A, Sengupta A, Seerapu GPK, et al. A novel SIRT1 inhibitor, 4bb induces apoptosis in HCT116 human colon carcinoma cells partially by activating p53. Biochem Biophys Res Commun, 2017, 488(3): 562-569.
18. Ye Z, Fang B, Pan J, et al. miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1. Oncol Rep, 2017, 37(6): 3244-3252.
19. Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol, 2009, 185(2): 203-211.
20. 安晓静, 金昌洙, 曹璋, 等. SIRT1、β-catenin 在胃癌组织中的表达及临床意义. 滨州医学院学报, 2013, 36(2) : 94-96.
21. 赵伟, 陈锐, 刘芮菡, 等. 沉默信息调节因子 1 对胃癌侵袭的影响及其机理研究. 中国普外基础与临床杂志, 2014, 21(4): 425-431.
22. Jiang B, Chen JH, Yuan WZ, et al. Prognostic and clinical value of Sirt1 expression in gastric cancer: A systematic meta-analysis. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(2): 278-284.
23. He C, Zhou Z, Jiang H, et al. Epithelial-mesenchymal transition is superior to vessels-encapsulate tumor cluster in promoting metastasis of hepatocellular carcinoma: a Morphological Evidence. J Cancer, 2017, 8(1): 39-47.
24. Zhang Y, An J, Lv W, et al. miRNA-129-5p suppresses cell proliferation and invasion in lung cancer by targeting microspherule protein 1, E-cadherin and vimentin. Oncol Lett, 2016, 12(6): 5163-5169.
25. Zhao L, Li Z, Chen W, et al. H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition. Oncol Lett, 2017, 13(1): 363-369.
26. Gao H, Lan X, Li S, et al. Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer. Tumour Biol, 2017, 39(5): 1010428317698368.
27. Zhang J, Chen XY, Huang KJ, et al. Expression of FoxM1 and the EMT-associated protein E-cadherin in gastric cancer and its clinical significance. Oncol Lett, 2016, 12(4): 2445-2450.
28. 苏林, 辛彦. E-cadherin和FSP-1/S100A4 在胃癌及其癌前病变中的表达与临床病理意义. 现代肿瘤医学, 2014, 22(12): 2903-2908.
29. 刘铭, 李宏, 张开立, 等. 胃癌组织中 caveolin-1 和 E-cadherin 表达及相关性的研究. 中国癌症杂志, 2010,20(11): 806-110.
30. Rong L, Wu J, Wang W, et al. Sirt 1 activator attenuates the bleomycin-induced lung fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT). Eur Rev Med Pharmacol Sci, 2016, 20(10): 2144-2150.
31. Lu J, Zhang M, Huang Z, et al. SIRT1 in B[a]P-induced lung tumorigenesis. Oncotarget, 2015, 6(29): 27113-27129.
32. Tian Z, Jiang H, Liu Y, et al. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1. Exp Cell Res, 2016, 343(2): 135-147.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Correlation study of expressions of silence signal regulating factor-1 and E-cadherin in gastric cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content